Onco-D-clare

A beacon of hope in empowering early detection of cancer

Onco-D–clare, an advanced cancer screening test designed to detect cancerous cells before symptoms manifest. Utilizing state-of-the-art technology that merges molecular biology with artificial neural networks, this liquid biopsy screening test provides individuals with vital insights into their cancer risk. The test represents a proactive step towards early cancer detection and informed well-being. Specifically tailored for individuals without symptoms but having a family history, this test offers a proactive approach to managing cancer risk.

How does Onco-D-clare work?

This revolutionary blood test for cancer detection utilizes molecular biology and machine learning to detect signs of cancer before symptoms appear.

Onco-D-clare analyzes the details of your gene expressions by combining gene expression analysis and machine learning algorithms.

After the collection of blood samples, peripheral blood mononuclear cells are isolated and subjected to comprehensive gene expression analysis.

With over 90 genes analyzed, this process evaluates the presence of cancerous cells with precision. Using molecular biology and artificial neural networks, Onco-D-clare accurately classifies samples as healthy or cancerous, enabling the detection of cancer at its earliest stages.

Seek help from our experts

What details does the test provide?

Gene expression of PBMCs

Peripheral Blood Mononuclear Cells (PBMCs) are key players in your immune system, including T cells, B cells, NK cells, and monocytes.

These cells are responsible for identifying and responding to abnormal cells in your body, including cancer cells.

By analyzing the gene expression of these PBMCs, we can detect the earliest signs of cancer before it even becomes visible in other tests.

How does it help?

Onco-D-clare, the blood test that can detect cancer, helps by identifying cancer at its earliest stages.

It thoroughly analyzes cancer risk for individuals with a family history of cancer even before symptoms manifest.

By providing comprehensive insights into your cancer risk profile, Onco-D-clare empowers you to take proactive steps toward managing your health.

Why choose Onco-D-clare?

Our test is clinically validated and boasts an impressive accuracy rate of approximately 82%. This level of reliability instills confidence in your results, enabling you to make informed decisions.

By analyzing over 90 genes as part of the Onco-D-clare test, we generate a comprehensive gene expression profile.

With Onco-D-clare, you gain the opportunity for timely intervention and improved outcomes.

Why choose Oncotrail?

Test details

To whom it is relevant: The test is recommended for those who have a family history of cancer, individuals who are exposed to occupational hazards, and individuals who wish for a cancer screening.